---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Co-prescribed/Concomitant therapies. Topics: Gonadotropin-releasing hormone or LHRH agonists for premenopausal women and men; Combination partners under study: CDK4/6, CDK4, PI3Kα, and mTOR inhibitors; Ribociclib: dosing and pharmacokinetic compatibility; Palbociclib: dosing and pharmacokinetic compatibility; 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Gonadotropin-releasing hormone or LHRH agonists for premenopausal women and men

> “Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

> “GnRH agonist requested for premenopausal women and for men.”

Source: [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)

> “Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

> “Male and pre- or peri-menopausal female participants must be willing to take a gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) agonist”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-2.1.2.12-2"></a>

### Combination partners under study: CDK4/6, CDK4, PI3Kα, and mTOR inhibitors

> “In combination, we are investigating palazestrant in multiple Phase 1/2 studies with CDK4/6 inhibitors (palbociclib or ribociclib), a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor (alpelisib), a mechanistic target of rapamycin (mTOR) inhibitor (everolimus), and a CDK4 inhibitor (atirmociclib).”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.1.2.12-3"></a>

### Ribociclib: dosing and pharmacokinetic compatibility

> “Here we present the data for 72 patients: 56 patients received 120 mg QD palazestrant and 16 patients received 90 mg QD palazestrant, all with 600 mg of ribociclib.”
> “Safety was consistent with the known safety profiles of each drug; palazestrant and ribociclib did not demonstrate any drug-drug interactions.”
> “The phase 3 dose of palazestrant as monotherapy or in combination with ribociclib is 90 mg QD.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

> “Ribociclib is a strong inhibitor of CYP3A4.”
> “Palazestrant is not a CYP3A4 inhibitor or inducer.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

> “90 mg QD palazestrant”
> “600 mg ribociclib (3 weeks on/1 week off)”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-2.1.2.12-4"></a>

### Palbociclib: dosing and pharmacokinetic compatibility

> “Palazestrant 120 mg in combination with palbociclib 125 mg was well tolerated.”
> “No drug-drug interaction between palazestrant and palbociclib was observed, in agreement with previous reports.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.12-5"></a>

### Antiemetics and proton pump inhibitors

> “In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.”
> “Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue [26].”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.12-6"></a>

### Colony-stimulating factors for neutropenia

> “While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.12-7"></a>

### Medications not permitted: QT-prolonging drugs and strong CYP3A4 inhibitors or inducers

> “Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.”
> “any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.12-8"></a>

### Washout of prior anticancer therapies

> “Prior CDK4/6 inhibitors, fulvestrant, alpelisib, everolimus, or poly-adenosine diphosphate ribose polymerase inhibitors were allowed if discontinued at least 2 weeks prior to the first dose of palazestrant.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Fulvestrant, <28 days prior ET, CDK4/6i, everolimus, tacrolimus, alpelisib, or PARP inhibitors, <14 days prior Any investigational cancer therapy, <28 days or 5 half-lives (whichever is shorter) prior”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.12-9"></a>

### Bone-modifying agents

No evidence found.

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
